INOPP Forum
Pharmacovigilance Requirements in Nicaragua
Quote from VigiServe Admin on February 8, 2026, 10:35 AMIn Nicaragua, Pharmacovigilance is overseen by the Ministry of Health (MINSA), specifically through the Dirección General de Regulación de Productos Farmacéuticos and the Centro Nacional de Farmacovigilancia (CNFV). The system is moderately developed and harmonized with Central American technical regulations.
1. Clinical Safety (Clinical Trials)
Clinical trials require MINSA approval and adherence to ICH GCP.
Expedited Reporting: Sponsors must report Suspected Unexpected Serious Adverse Reactions (SUSARs) consistent with ICH E2A:
Fatal or Life-Threatening: Within 7 calendar days.
Other Serious Unexpected: Within 15 calendar days.
Periodic Reporting: Development Safety Update Reports (DSURs) are required annually or periodically.
Submission: Reports are submitted via MINSA channels (electronic or forms).
2. Post-Marketing Pharmacovigilance
Post-approval obligations emphasize local responsibility and regional alignment.
Personnel: A Local Responsible Person for Pharmacovigilance (RLFV) is mandatory. This individual must be a qualified professional (pharmacist or physician) residing in Nicaragua and registered with MINSA.
Documentation: While a formal PSMF is not explicitly mandatory in public sources, documented PV procedures (SOPs) are required for inspections.
Incident Reporting (ICSRs):
Serious Cases: Report within 15 calendar days.
Non-Serious Cases: Report within 90 calendar days.
Risk & Periodic Reporting:
PSURs: Frequency is not rigidly standardized; typically submitted upon request or during renewals.
RMPs: Mandatory for new products, biologics, vaccines, and high-risk medicines.
Summary of Requirements
Component Requirement in Nicaragua Regulatory Authority MINSA (Ministry of Health) Regional Framework Central American Harmonization Local Personnel Mandatory RLFV (Pharmacist/Physician) PSMF Not explicitly mandatory (Docs required) Serious ICSR Timeline 15 Days Clinical Reporting SUSARs (7/15 days) RMPs Mandatory (High Risk/New)
In Nicaragua, Pharmacovigilance is overseen by the Ministry of Health (MINSA), specifically through the Dirección General de Regulación de Productos Farmacéuticos and the Centro Nacional de Farmacovigilancia (CNFV). The system is moderately developed and harmonized with Central American technical regulations.
1. Clinical Safety (Clinical Trials)
Clinical trials require MINSA approval and adherence to ICH GCP.
-
Expedited Reporting: Sponsors must report Suspected Unexpected Serious Adverse Reactions (SUSARs) consistent with ICH E2A:
-
Fatal or Life-Threatening: Within 7 calendar days.
-
Other Serious Unexpected: Within 15 calendar days.
-
-
Periodic Reporting: Development Safety Update Reports (DSURs) are required annually or periodically.
-
Submission: Reports are submitted via MINSA channels (electronic or forms).
2. Post-Marketing Pharmacovigilance
Post-approval obligations emphasize local responsibility and regional alignment.
-
Personnel: A Local Responsible Person for Pharmacovigilance (RLFV) is mandatory. This individual must be a qualified professional (pharmacist or physician) residing in Nicaragua and registered with MINSA.
-
Documentation: While a formal PSMF is not explicitly mandatory in public sources, documented PV procedures (SOPs) are required for inspections.
-
Incident Reporting (ICSRs):
-
Serious Cases: Report within 15 calendar days.
-
Non-Serious Cases: Report within 90 calendar days.
-
-
Risk & Periodic Reporting:
-
PSURs: Frequency is not rigidly standardized; typically submitted upon request or during renewals.
-
RMPs: Mandatory for new products, biologics, vaccines, and high-risk medicines.
-
Summary of Requirements
| Component | Requirement in Nicaragua |
| Regulatory Authority | MINSA (Ministry of Health) |
| Regional Framework | Central American Harmonization |
| Local Personnel | Mandatory RLFV (Pharmacist/Physician) |
| PSMF | Not explicitly mandatory (Docs required) |
| Serious ICSR Timeline | 15 Days |
| Clinical Reporting | SUSARs (7/15 days) |
| RMPs | Mandatory (High Risk/New) |